HIF on why voluntary licensing of patents is not required
In book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss why voluntary licensing of patents is not required.
Page 22
Voluntary Licensing
Search Results for: drug patents
Misc notes on Compulsory Licensing of Patents
Worth reading first
March 8, 2007, Recent examples of the use of compulsory licensing of patents, revised March 31, 2007.
Misc
June 9, 2007. When customs authorities may allow infringing goods to be imported into the United States.
Colombian Submission to the WHO IGWG negotiation favors drug company positions on IP
By resolution WHA 59.24, the WHO’s Intergovernmental Working Group on Public Health, Innovation, and Intellectual Property (IGWG) has the goal of producing a Global Strategy and Plan of Action that will implement the CIPIH report recommendations and “secure an enhanced and sustainable basis for needs-driven, essential health research and development relevant to diseases that disproportionately affect developing countries, proposing cle Continue Reading
Letter asking WHO review of the Essential Drugs List (EDL) as it relates to patented products
The following is the text of a letter to Dr. Margaret Chan, Director-General Elect, World Health Organization (WHO), asking for a review of the Essential Drugs List (EDL) as it relates to patented products. Consumer Project on Technology http://www.cptech.org December… Continue Reading
U.S. DoS Cable: GOB REACHES PRICING AGREEMENTS ON THREE MORE AIDS DRUGS
R 302037Z – January 30, 2004
FM AMCONSUL SAO PAULO
TO SECSTATE WASHDC 0593
SUBJECT: BRAZIL UPDATE: GOB REACHES PRICING AGREEMENTS ON THREE MORE AIDS DRUGS
Continue Reading
Implementing TRIPS safeguards with particular attention to administrative models for compulsory licensing of patents
Implementing TRIPS safeguards with particular attention to administrative models for compulsory licensing of patents WHO meeting in Harare, ZimbabweAugust 21, 2001(with additional references to November Doha declaration) James LoveConsumer Project on Technology I. Introduction. TRIPS obligations raise broad public health… Continue Reading
2000: How much does it cost to develop a new drug?
How much does it cost to develop a new drug? James Love Consumer Project on Technology http://www.cptech.org April 2, 2000 Prepared for the April 2, 2000 meeting of the MSF Working Group on R&D in Geneva. How much does it… Continue Reading
Brief note on the abuse of Orphan Drug programs in creating monopolies
CPT has been highly critical of the exclusive marketing provisions in the US and the proposed EU orphan drug acts. Pharmaceutical companies now obtain 20 year patents for inventions, and investments in clinical trials and other research required for drug… Continue Reading
1994: Pricing of Drugs Developed with Public Funds
Comments Presented to the Second NIH CRADA Forum September 8, 1994 James Love Director, Taxpayer Assets Project P.O. Box 19367, Washington, DC 20036 I. Introduction My name is James Love. I work for the Center for Study of Responsive Law,… Continue Reading
1994: Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States
Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States James Packard Love* Presented at XV Asamblea General de la Asociaión Latinoamericana de Industrias Farmacéuticas San Carlos de Bariloche – Río Negro – Argentina 11… Continue Reading